KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Cash & Equivalents: 2009-2025

Historic Revenue - Interest and Investment Income for Exact Sciences (EXAS) over the last 1 years, with Mar 2011 value amounting to $76.3 million.

  • Exact Sciences' Cash & Equivalents rose 34.00% to $789.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $789.0 million, marking a year-over-year increase of 34.00%. This contributed to the annual value of $600.9 million for FY2024, which is 0.74% down from last year.
  • Exact Sciences' Cash & Equivalents amounted to $789.0 million in Q3 2025, which was up 20.08% from $657.1 million recorded in Q2 2025.
  • Exact Sciences' 5-year Cash & Equivalents high stood at $1.1 billion for Q1 2021, and its period low was $189.8 million during Q1 2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $594.6 million (2023), whereas its average is $553.3 million.
  • Data for Exact Sciences' Revenue - Interest and Investment Income shows a peak YoY spiked of 1,510.26% (in 2011) over the last 5 years.
  • Over the past 3 years, Exact Sciences' Revenue - Interest and Investment Income (Quarterly) stood at $6.1 million in 2009, then soared by 1,208.73% to $79.8 million in 2010, then surged by 1,510.26% to $76.3 million in 2011.
  • Its Cash & Equivalents stands at $789.0 million for Q3 2025, versus $657.1 million for Q2 2025 and $347.1 million for Q1 2025.